Krystal Biotech, Inc.

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical…

Biotechnology

US, Pittsburgh [HQ]

Financials

Analysts

Wall Street · Earnings · Institutional Sentiment

A comprehensive analysis section that covers unveiling insights about Krystal Biotech, Inc.'s gradings, price targets and earnings estimates.

Earnings

See the historical earnings and what wall street analysts forecasted and
forecast for future earnings.

Reported

Past Estimate Consensus

Future Estimate Consensus

EPS Revenue EBITDA EBIT SGA

All monetary values are presented in USD ($). E stands for Estimate.
FY	EPS		Revenue [mil.]		Profit [mil.]		EBITDA [mil.]		EBIT [mil.]		Expenses · SGA [mil.]
		E		E		E		E		E		E
2023	-5.4900	-0.120	0	36	-139	-3	-110	21	-124	21	77	42

Institutional Sentiment

Wall Street · Earnings · Institutional Sentiment

The institutional sentiment measures the direction of new stock gradings
and price targets while comparing them Year-over-Year. We've limited the grading institutes to those we see as top-tier and update this data every month.

Morgan Stanley

1Y Ago:

n/a

Prev. Grade

n/a

Latest

n/a

JP Morgan Chase

1Y Ago:

n/a

Prev. Grade

n/a

Latest

n/a

Citigroup

1Y Ago:

Underweight

Prev. Grade

n/a

Nov. 6, 2024

Underweight

Overall Consensus

Here we aggregate the price targets and gradings of all IBs/AMCs/Brokerage firms inside our database to draw a bigger picture.

Grading Consensus

Click to each, to see the grade

Price Target Consensus

-14.196% $25.83 · MISS

Nov. 6, 2024

Price Then

$174.41

Price Target

$207.78

Price Now

$181.95